Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Falls 8.2% – Here’s What Happened

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX)’s share price was down 8.2% during mid-day trading on Tuesday. The company traded as low as $2.30 and last traded at $2.36. 2,676,668 shares traded hands during trading, an increase of 6% from the average session volume of 2,520,738 shares. The stock had previously closed at $2.57.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: FDA Fast Track designation for PSV359: The FDA granted Fast Track status to PSV359 for adults with locally advanced, unresectable or metastatic FAP-positive solitary fibrous tumors, a rare cancer with limited treatment options. The designation can provide more frequent FDA interaction and may support rolling review, accelerated approval or priority review if additional criteria are met. Early imaging data showed strong tumor uptake and rapid kidney clearance. Perspective Therapeutics Granted Fast Track Designation for PSV359
• Positive Sentiment: Positive analyst stance: BTIG Research reaffirmed its “Buy” rating and set a $14 price target, substantially above the recent trading level. Separately, coverage from 11 brokerages was reported as averaging a “Buy” recommendation, with nine buys, one strong buy and one hold. These ratings may improve sentiment but remain dependent on future clinical execution.
• Positive Sentiment: Upcoming clinical data: Data from CATX’s [²¹²Pb]VMT-α-NET program were accepted for presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium in November, creating a potential near-term catalyst for its broader radiopharmaceutical pipeline. Perspective Therapeutics Announces Acceptance of VMT-alpha-NET Data
• Neutral Sentiment: Mixed institutional positioning: BlackRock and several other funds increased holdings, while Opaleye Management, Patient Square Capital and Morgan Stanley reduced or eliminated positions. This indicates continued institutional interest but also significant disagreement about CATX’s outlook.
• Negative Sentiment: Insider selling and development risk: Reported insiders made seven open-market sales and no purchases over the past six months. PSV359 remains in Phase 1/2a testing, and Fast Track does not guarantee efficacy or approval. Clinical delays, unfavorable results, regulatory setbacks and the company’s need for additional capital remain important risks.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on CATX shares. Piper Sandler dropped their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. BTIG Research reiterated a “buy” rating and set a $14.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday. Bank of America decreased their price objective on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, August 14th. BMO Capital Markets set a $11.00 target price on Perspective Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Finally, Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $11.50.

Perspective Therapeutics Price Performance

The stock’s 50-day moving average is $2.96 and its 200-day moving average is $3.42.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. On average, equities analysts forecast that Perspective Therapeutics, Inc. will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Commodore Capital LP bought a new position in Perspective Therapeutics during the 1st quarter valued at $26,424,000. Avidity Partners Management LP raised its stake in shares of Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after buying an additional 2,839,266 shares in the last quarter. Affinity Asset Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 954.9% in the first quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock valued at $13,196,000 after buying an additional 2,864,582 shares during the period. Spruce Street Capital LP acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at $10,955,000. Finally, Yu Fan bought a new position in Perspective Therapeutics during the first quarter valued at about $4,401,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company’s approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective’s proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.